Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

Protein kinase B (PKB; PKBA; AKT; AKT1)

Studies in human tissue and cell culture suggest antagonizing AKT signaling could be useful for treating BRAF inhibitor-resistant melanoma. In 100 tumor biopsies from 44 patients with BRAF inhibitor-resistant melanoma, activating mutations in a range of AKT pathway regulators, including AKT itself, were found in 22% of resistant tumor biopsies. In cell culture, tumor cells with activating AKT mutations had higher AKT pathway signaling and greater survival in the presence of a BRAF inhibitor than controls lacking the AKT mutations. Next steps include clinical testing of AKT inhibitors in combination with inhibitors of BRAF or MAPK signaling, another pathway implicated in BRAF inhibitor-resistant melanoma.
Tafinlar dabrafenib (GSK2118436) from GlaxoSmithKline plc and Zelboraf vemurafenib from Roche and Daiichi Sankyo Co. Ltd. are BRAF inhibitors marketed to treat BRAF-mutant melanoma.
At least 12 companies including Roche and GSK have AKT inhibitors in preclinical through Phase II testing for a range of solid tumors including BRAF-mutant melanoma (see The next battle line against melanoma, page 4).

SciBX 7(1); doi:10.1038/scibx.2014.13
Published online Jan. 9, 2014

Patent pending for an assay to identify tumors with activating mutations in AKT; licensing status undisclosed

Shi, H. et al. Cancer Discov.; published online Nov. 21, 2013;
doi:10.1158/2159-8290.CD-13-0279
Shi, H. et al. Cancer Discov.; published online Nov. 21, 2013;
doi:10.1158/2159-8290.CD-13-0642
Contact: Roger S. Lo, University of California, Los Angeles, Calif.
e-mail:

rlo@mednet.ucla.edu